evrazkarЕвразийский Кардиологический ЖурналEurasian heart journal2225-16852305-0748Евразийская ассоциация кардиологовevrazkar-11Research ArticleКЛИНИЧЕСКИЙ СЛУЧАЙCLINICAL CASEМИНЗДРАВ РОССИИ ОДОБРИЛ НОВЫЙ ПРЕПАРАТ ДЛЯ ЛЕЧЕНИЯ ГИПЕРХОЛЕСТЕРИНЕМИИ ЭВОЛОКУМАБ БИОТЕХНОЛОГИЧЕСКОЙ КОМПАНИИ АМДЖЕН. ЭТО ПЕРВЫЙ В МИРЕ ОДОБРЕННЫЙ ИНГИБИТОР ФЕРМЕНТА PCSK9, ПРЕДНАЗНАЧЕННЫЙ ДЛЯ СНИЖЕНИЯ УРОВНЯ ХОЛЕСТЕРИНА В КРОВИМИНЗДРАВ РОССИИ ОДОБРИЛ НОВЫЙ ПРЕПАРАТ ДЛЯ ЛЕЧЕНИЯ ГИПЕРХОЛЕСТЕРИНЕМИИ ЭВОЛОКУМАБ БИОТЕХНОЛОГИЧЕСКОЙ КОМПАНИИ АМДЖЕН. ЭТО ПЕРВЫЙ В МИРЕ ОДОБРЕННЫЙ ИНГИБИТОР ФЕРМЕНТА PCSK9, ПРЕДНАЗНАЧЕННЫЙ ДЛЯ СНИЖЕНИЯ УРОВНЯ ХОЛЕСТЕРИНА В КРОВИРедакционнаястатьяEditorialArticlenoemail@neicon.ru201730032017016263Copyright © Редакционная с., 20172017Редакционная с.Editorial a.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.heartj.asia/jour/article/view/11
.
.
ReferencesAmgen Data on File, Investigator Brochure.Amgen Data on File, Investigator Brochure.World Health Organization. Quantifying Selected Major Risks to Health. In: The World Health Report 2002 - Reducing Risks, Promoting Healthy Life. Geneva. 2002:49-97.World Health Organization. Quantifying Selected Major Risks to Health. In: The World Health Report 2002 - Reducing Risks, Promoting Healthy Life. Geneva. 2002:49-97.Merck Manuals website. http://www.merckmanuals.com/professional/ endocrine_and_metabolic_disorders/lipid_disorders/dyslipidemia.html. Accessed July 2015.Merck Manuals website. http://www.merckmanuals.com/professional/ endocrine_and_metabolic_disorders/lipid_disorders/dyslipidemia.html. Accessed July 2015.American Heart Association (2014). Why Cholesterol Matters. http://www. heart.org/HEARTORG/Conditions/Cholesterol/WhyCholesterolMatters/Why-Cholesterol-Matters_UCM_001212_Article.jsp. Accessed July 2015.American Heart Association (2014). Why Cholesterol Matters. http://www. heart.org/HEARTORG/Conditions/Cholesterol/WhyCholesterolMatters/Why-Cholesterol-Matters_UCM_001212_Article.jsp. Accessed July 2015.World Health Organization. Global Status Report on Noncommunicable Diseases 2014. Geneva, 2014.World Health Organization. Global Status Report on Noncommunicable Diseases 2014. Geneva, 2014.Halcox JP, et al. Low Rates of Both Lipid-Lowering Therapy Use and Achievement of Low-Density Lipoprotein Cholesterol Targets in Individuals at HighRisk for Cardiovascular Disease across Europe. PLoS One. 2015;10(2).Halcox JP, et al. Low Rates of Both Lipid-Lowering Therapy Use and Achievement of Low-Density Lipoprotein Cholesterol Targets in Individuals at HighRisk for Cardiovascular Disease across Europe. PLoS One. 2015;10(2).Leal J, et al. Economic Costs. In: Nichols M, et al. European Cardiovascular Disease Statistics 2012.Leal J, et al. Economic Costs. In: Nichols M, et al. European Cardiovascular Disease Statistics 2012.National Human Genome Research Institute. Learning About Familial Hypercholesterolemia. http://www.genome.gov/25520184. Accessed July 2015.National Human Genome Research Institute. Learning About Familial Hypercholesterolemia. http://www.genome.gov/25520184. Accessed July 2015.Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial Hypercholesterolaemia is Underdiagnosed and Undertreated in the General Population: Guidance for Clinicians to Prevent Coronary Heart Disease. Eur Heart J. 2013;34:3478-3490.Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial Hypercholesterolaemia is Underdiagnosed and Undertreated in the General Population: Guidance for Clinicians to Prevent Coronary Heart Disease. Eur Heart J. 2013;34:3478-3490.Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. N Engl J Med. 2015;372:1500-1509.Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. N Engl J Med. 2015;372:1500-1509.Koren MJ, Lundqvist P, Bolognese M, et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol. 2014;63:2531-2540.Koren MJ, Lundqvist P, Bolognese M, et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol. 2014;63:2531-2540.Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of evolocumab or ezetimibe added to moderate or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia. The LAPLACE-2 randomized clinical trial. JAMA. 2014;311:1870-1882.Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of evolocumab or ezetimibe added to moderate or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia. The LAPLACE-2 randomized clinical trial. JAMA. 2014;311:1870-1882.Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:331-340.Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:331-340.Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63:2541-2548.Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63:2541-2548.Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, doubleblind, placebo-controlled trial. Lancet. 2015;385:341-50.Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, doubleblind, placebo-controlled trial. Lancet. 2015;385:341-50.Blom DJ, Hala T, Bolognese M. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370:1809-1819.Blom DJ, Hala T, Bolognese M. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370:1809-1819.Koren MJ, Giugliano RP, Raal FJ, et al. Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia: 52-Week Results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) Randomized Trial. Circulation. 2014;129:234-243.Koren MJ, Giugliano RP, Raal FJ, et al. Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia: 52-Week Results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) Randomized Trial. Circulation. 2014;129:234-243.Lopez D. PCSK9: An enigmatic protease. Biochimica et Biophysica Acta. 2008;1781:184-191.Lopez D. PCSK9: An enigmatic protease. Biochimica et Biophysica Acta. 2008;1781:184-191.World Health Organization. Cardiovascular diseases (CVDs) fact sheet. http:// www.who.int/mediacentre/factsheets/fs317/en/. Accessed July 2015.World Health Organization. Cardiovascular diseases (CVDs) fact sheet. http:// www.who.int/mediacentre/factsheets/fs317/en/. Accessed July 2015.
The authors declare that there are no conflicts of interest present.